Joining a psychedelic clinical trial is more accessible than most people realize. The process takes several weeks but is free — and for many people, it's the only way to legally access these treatments in 2026.
Go to ClinicalTrials.gov and search for your condition + compound (e.g., "psilocybin treatment-resistant depression"). Filter by "Recruiting" status. Filter by your country/state. As of 2026, there are 100+ active psychedelic studies on the registry.
Every trial has inclusion and exclusion criteria. Common inclusion criteria: adults 18+, specific diagnosis (e.g., treatment-resistant depression = failed 2+ antidepressants), stable housing. Common exclusion criteria: certain heart conditions, personal or family history of psychosis, current pregnancy, some medications (especially MAOIs and lithium). Read these carefully before reaching out.
Each ClinicalTrials.gov listing has a "Contact" section with phone and email for the trial coordinator. Reach out directly — express interest and ask for a screening call. Be honest about your medical history. Sites want qualified participants and will guide you through the process.
Most trials require 2–4 screening visits before the treatment phase. These assess your baseline health, psychiatric state, and confirm eligibility. Blood work, psychological assessments, and medical history review are standard. This process takes 4–8 weeks typically.
Once enrolled, you'll have preparation sessions (1–3 meetings with your assigned therapist), then the psilocybin or MDMA dosing session(s), then integration sessions afterward. The full protocol typically spans 3–6 months. You'll receive the experimental compound at no cost along with trained therapist support throughout.
Large Phase 3 trials like COMPASS COMP360 operate at dozens of sites across the US and EU. If the nearest site has a full waitlist, check other sites in the same trial — some may have shorter waits. The ClinicalTrials.gov listing shows all active sites for each trial.
These are the trials that matter most for regulatory progression — and for patient access right now. OOTWOracle monitors all of these daily for news and data releases that affect our prediction scores.
The most advanced psilocybin trial globally. Tests synthetic psilocybin (25mg single dose) for TRD. Positive Phase 2b results published 2022. Phase 3 is the pivotal study needed for FDA NDA. Sites across US, UK, Canada, EU, Australia.
View on ClinicalTrials.gov →Usona's non-profit mission: make psilocybin therapy widely accessible. Testing psilocybin for non-treatment-resistant MDD (a much larger patient population than TRD). Phase 2b ongoing. FDA Breakthrough Therapy Designation received. Sites at multiple US academic medical centers.
Search Usona Trials →Building on the landmark 2022 NYU/Hopkins psilocybin + AUD study. Johns Hopkins is running multiple Phase 2 psilocybin studies across conditions including major depressive disorder, tobacco addiction, Alzheimer's-related depression, and alcohol use disorder.
Search Hopkins Trials →NYU Langone's Psychedelic Medicine research program runs multiple active studies. Known for landmark psilocybin + existential distress trials (cancer patients) and 2022 psilocybin + AUD study. Current focus includes OCD, MDD, and further AUD work.
Search NYU Trials →After the August 2024 FDA CRL, MAPS/Lykos is preparing a Phase 3 resubmission addressing cardiac safety and therapy fidelity concerns. Additional data collection sites remain active. Compassionate use programs continue for treatment-refractory PTSD. New independent MDMA trials are also enrolling.
Search MDMA PTSD Trials →Following the 2025-2026 wave of psilocybin + neuroplasticity studies, multiple academic centers are now actively studying psilocybin for Alzheimer's-related depression and cognitive decline. This is an emerging area with strong early signal data — and one that OOTWOracle's agents actively track.
Search Alzheimer's Trials →Psychedelic clinical research in 2026 covers a remarkably wide range of conditions. Here is what is actively being studied:
OOTWOracle's 8-agent system generates daily confidence scores on which trial programs will result in FDA approval. These reflect probability assessments based on trial design quality, Phase 2 effect sizes, competitive landscape, and FDA precedent.
Most advanced program. Phase 2b data is strong (+6.6 MADRS points vs. placebo at 25mg). Phase 3 is underway. Timeline to FDA submission: 2027. To approval: 2028-2029.
Non-profit model with non-proprietary psilocybin. Breakthrough Therapy Designation. Targets MDD (200M+ patients globally vs. TRD's ~100M). Higher market but slightly longer timeline than COMPASS.
CRL in 2024 was a major setback. Resubmission requires addressing cardiac safety concerns. Australian real-world data is helping. New Phase 3 design is more rigorous. Realistic approval: 2029-2031.
Stanford's 2023 veteran study showed remarkable results. Cardiac risk profile requires very controlled clinical protocols. Texas VETS Act created state-level access. Federal pathway is 5+ years away but being laid out now.
Go to ClinicalTrials.gov and search for "psilocybin" filtered to "Recruiting" status. Find trials that match your condition and location. Read the eligibility criteria carefully, then contact the trial coordinator directly (listed on each trial page). The process from first contact to first session typically takes 4–8 weeks of screening visits. Treatment and therapist support are always provided at no cost to participants.
COMPASS Pathways' COMP360 is the most advanced psilocybin clinical trial globally — a Phase 3 pivotal study for treatment-resistant depression. It tests a single 25mg dose of synthetic psilocybin with psychological support. Phase 2b results published in 2022 showed a statistically significant reduction in depression symptoms. The Phase 3 trial is the data COMPASS needs to file a New Drug Application (NDA) with the FDA and EMA. Trial ID: NCT05548439.
Yes, most trials compensate participants for time and travel — typically $50–$150 per visit, with total compensation of $400–$2,000+ for the complete study period. More importantly, you receive the experimental treatment (psilocybin or MDMA sessions) and trained therapist support completely free of charge. For many participants, this is the only way to access these treatments legally in 2026 outside of Oregon or Colorado's regulated programs.
It depends on the specific trial. Many psilocybin trials require a washout period from certain medications before enrollment — typically 2–4 weeks off SSRIs/SNRIs (which blunt psilocybin's effects), and longer for some other medications. MAOIs and lithium are typically excluded entirely due to safety interactions. Some trials allow stable, low-dose medications. The trial coordinator will review your medication list during screening. Don't stop medications on your own — work with your psychiatrist and the trial team.
Yes. Following research showing psilocybin's neuroplasticity and neurogenesis effects, multiple academic centers are actively running Phase 2 trials for Alzheimer's disease-related depression and cognitive decline. OOTWOracle has been tracking this since a landmark 2025 study showed psilocybin produced measurable hippocampal neurogenesis in older adults. Search ClinicalTrials.gov for "psilocybin Alzheimer" or "psilocybin dementia" filtered to Recruiting to find active studies.
OOTWOracle tracks trial enrollment updates, interim data releases, FDA advisory committee meetings, and DEA scheduling actions daily. Get real-time AI predictions on which studies will change regulation.
Oracle Chamber → Psilocybin FDA Tracker →More OOTWOracle analysis on the regulatory landscape: